Fig. 4

The effects of the combination of CD36 and PI3K inhibitors in HER2-positive PTEN-loss breast cancer cells. (a) The effects on the proliferation of HCC1569 cells treated with the CD36 inhibitor. The cell numbers were assessed in SSO-treated cells for 72 h using the WST-1 assay and presented as a percentage of the untreated control (mean ± SEM). The effects on cell proliferation of HCC1569 cells treated with the CD36 inhibitor in combination with alpelisib (b) or inavolisib (c) for 72 h. The cell numbers were assessed by the WST-1 assay and presented as a percentage of the untreated control (mean ± SEM). (d, e) The modulated protein levels of SCD-1 and CD36 were evaluated by western blotting in HCC1569 cells treated with SSO plus alpelisib (d) or inavolisib (e) for 24 h. The protein expression is relative to the untreated control (mean ± SEM), *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. (f) Isobologram analysis for the combined treatments of alpelisib (left) or inavolisib (right) with SSO in HCC1569 cells for 72 h. CI < 1 indicated synergistic effect. A: alpelisib; I: inavolisib; S: SSO